BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3047 related articles for article (PubMed ID: 28640612)

  • 1. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.
    Li L; Hu S; Chen X
    Biomaterials; 2018 Jul; 171():207-218. PubMed ID: 29704747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Progress in CRISPR/Cas9 Technology.
    Mei Y; Wang Y; Chen H; Sun ZS; Ju XD
    J Genet Genomics; 2016 Feb; 43(2):63-75. PubMed ID: 26924689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for
    Wei T; Cheng Q; Farbiak L; Anderson DG; Langer R; Siegwart DJ
    ACS Nano; 2020 Aug; 14(8):9243-9262. PubMed ID: 32697075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
    Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
    Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different Methods of Delivering CRISPR/Cas9 Into Cells.
    Chandrasekaran AP; Song M; Kim KS; Ramakrishna S
    Prog Mol Biol Transl Sci; 2018; 159():157-176. PubMed ID: 30340786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
    Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
    Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivering CRISPR: a review of the challenges and approaches.
    Lino CA; Harper JC; Carney JP; Timlin JA
    Drug Deliv; 2018 Nov; 25(1):1234-1257. PubMed ID: 29801422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CRISPR/Cas9 system: Their delivery, in vivo and ex vivo applications and clinical development by startups.
    Song M
    Biotechnol Prog; 2017 Jul; 33(4):1035-1045. PubMed ID: 28440027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges.
    Luther DC; Lee YW; Nagaraj H; Scaletti F; Rotello VM
    Expert Opin Drug Deliv; 2018 Sep; 15(9):905-913. PubMed ID: 30169977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two Distinct Approaches for CRISPR-Cas9-Mediated Gene Editing in Cryptococcus neoformans and Related Species.
    Wang P
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29898980
    [No Abstract]   [Full Text] [Related]  

  • 13. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
    Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
    J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a CRISPR/Cas9 genome editing toolbox for Corynebacterium glutamicum.
    Liu J; Wang Y; Lu Y; Zheng P; Sun J; Ma Y
    Microb Cell Fact; 2017 Nov; 16(1):205. PubMed ID: 29145843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in CRISPR/CAS9 Delivery: Potential Roles of Nonviral Vectors.
    Li L; He ZY; Wei XW; Gao GP; Wei YQ
    Hum Gene Ther; 2015 Jul; 26(7):452-62. PubMed ID: 26176432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromatin accessibility and guide sequence secondary structure affect CRISPR-Cas9 gene editing efficiency.
    Jensen KT; Fløe L; Petersen TS; Huang J; Xu F; Bolund L; Luo Y; Lin L
    FEBS Lett; 2017 Jul; 591(13):1892-1901. PubMed ID: 28580607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery of CRISPR/Cas9 for therapeutic genome editing.
    Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
    J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
    Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 153.